Request Processed
Your registration request has been processed. We will contact you soon.
Register
First name
Last name
Email
Company
Toggle navigation
Toggle navigation
Login
Register
About
Contact Us
1
2
3
4
5
…
Next ›
Last »
Pfizer Faces Skeptical FDA For Talzenna “All Comers” Prostate Cancer Indication, But Can ODAC Say No To Survival Benefit?
May 16, 2025
Janssen Darzalex Faspro For Smoldering Myeloma: PFS Benefit In “Precursor” Condition Doubted By FDA Ahead Of ODAC; New CBER Director Prasad Is Also A Skeptic
May 16, 2025
Genentech Columvi Confirmatory Trial Questioned By FDA; ODAC Will Be Asked If Positive Results Apply To US Population Given Impact Of China/Asia Patients On Efficacy Outcomes
May 16, 2025
Prevision Policy Clips | GDUFA IV Reauthorization Kick-Off Meeting Set For July 11, FDA Formally Announces July 14 PDUFA VIII Public Meeting
May 16, 2025
Prevision Policy Clips | Biohaven Troriluzole For SCA Will Go Before An FDA Advisory Committee
May 15, 2025
RFK Embraces Streamlined Development Path For New Drugs During Budget Hearings; Says Industry 340B Concerns Need Attention, But Pledges To Protect Rural Providers
May 14, 2025
CMMI Will Look To More Drug Demos In Future Years, Sickle Cell Gene Therapy Model May Be Blueprint For Drugs That Get At “Root Causes” Of Conditions
May 14, 2025
Prevision Policy Clips | Finance Committee PBM Legislation Will Advance Following Reconciliation Process, Sen. Grassley (R-Iowa) Says
May 14, 2025
CMS Outlines Medicare Drug Price Re-Negotiation Process; Few Of First 25 Products Likely To Be Eligible – But Xarelto And Tradjenta May Be
May 13, 2025
Medicare Price Negotiation Year 3: CMS Proposes Tweaks But No Major Revisions, Suggests Biologic SubQ Combos May Not Be Separate From Original Brand
May 13, 2025
CBER Touts Cell/Gene Therapy “Platform Technology,” CMC Pilot To Speed Development; Others Float Public Cost Recovery Model For Rare Diseases
May 13, 2025
Prevision Policy Clips | Price Negotiation For Year 3: CMS Leaves Key Product Selection Criteria Unchanged In Draft Guidance
May 13, 2025
Drug Manufacturers Get Some Of What They Want In House Reconciliation Bill: Orphan Drugs Get A Reprieve; PBM Reforms Are Present, “Pill Penalty” Fix Is Absent
May 12, 2025
MFN Policy 2.0: Manufacturers Have 30-Day Window To Avoid New Pricing Rules Via Direct-To-Consumer Sales; International Price “Equalization” Is Goal
May 12, 2025
Prevision Policy Clips | MFN Policy 2.0: Manufacturers Have A Chance To “Negotiate”
May 12, 2025
Prevision Policy Clips | FDA TV? Commissioner Makary, CBER Director Prasad
May 9, 2025
Pushing AI At FDA: Agency Plans “Aggressive” Rollout For AI Platform To Aid “Scientific Review”; Commissioner Cites First “AI-Assisted” Review Milestone
May 8, 2025
Prevision Policy Clips | PDUFA Reauthorization Kick Off Meeting Set For July 14
May 8, 2025
Opioid Post-Marketing Studies Praised For “Rigor,” But FDA Committee Wary Of Labeling Changes; Discussion Highlights Ongoing Concerns About Long-Term Efficacy
May 7, 2025
HHS Deputy Nominee O’Neill Cites Value Of AI, Support For Medicare Drug Price Negotiation And Vaccines During Confirmation Hearing; RFK “Doing A Great Job”
May 7, 2025
Prevision Policy Clips | FDA Schedules Last-Minute ODAC Review Of Four Oncology Drugs May 20-21
May 7, 2025
CBER Director Vinay Prasad Solidifies FDA’s Anti-Industry Identity, Brings Increased Scrutiny To Use Of Accelerated Approval In Cancer, Gene Therapies
May 6, 2025
White House Drug Manufacturing EO Seeks To Streamline Domestic Site Inspections, Accelerate Foreign Audits – But RIFs, Long-Standing Challenges Will Be Reality Check
May 6, 2025
Prevision Policy Clips | FDA Directed To Streamline Domestic Inspections, Accelerate Foreign Ones
May 6, 2025
Prevision Policy Clips | FDA Not Mentioned In “Skinny Budget” Unveiled By Trump Administration May 2
May 5, 2025
1
2
3
4
5
…
Next ›
Last »